logo
'Terrible setback': Indigenous tourism industry says it's suffering as U.S. bookings decline

'Terrible setback': Indigenous tourism industry says it's suffering as U.S. bookings decline

CBC5 hours ago
Social Sharing
Indigenous tourism operators in Canada say they're worried about their future as the number of American guests plummets amid political tensions between Canada and the U.S.
Indigenous tourism has been booming in Canada in recent years as people look for unique travel experiences and seek to learn more about Indigenous culture.
According to the Conference Board of Canada's latest report, the Indigenous tourism sector generated an estimated $3.7 billion in revenues in 2023, directly contributing $1.6 billion to Canada's gross domestic product.
The industry is warning hundreds of jobs and millions of dollars are now at stake.
Dean Werk, the Métis owner of Great River Fishing Adventures, which operates on the Fraser River in B.C., said his business has lost about $250,000 this season since U.S. President Donald Trump's trade war began.
"It's a terrible setback," he said. "This is actually tragic and terribly impactful to all Indigenous tourism businesses in Canada."
'Such an important market'
Werk is not alone. In April, the Indigenous Tourism Association of Canada surveyed about 100 Indigenous tourism operators that market to American clients. Nearly 70 per cent reported a drop in U.S. bookings.
Association president and CEO Keith Henry said American tourists account for up to 35 per cent of overall revenue for Indigenous tourism operators.
"Hundreds of jobs, if not thousands of jobs, are at stake here, if the season does continue to see declines," Henry said.
He estimated the industry could lose as much as $500 million this summer.
"We've been building Indigenous tourism and we've been focusing on the U.S. market … for many years," Henry said, adding that the U.S. is the sector's largest international market.
"It's such an important market for us."
WATCH | Indigenous businesses say they are losing U.S. clients:
Indigenous tourism operators see drop in U.S. visitors
4 days ago
Duration 2:00
Talaysay Campo, co-owner of Talaysay Tours, which offers nature walks, among other experiences around B.C., said U.S. corporate groups totalling about 1,000 guests have cancelled bookings for this summer.
"We've been building these relationships for the past 21 years, and to see them go, it makes me sad," she said.
She said total sales and revenue from Americans totalled about 33 per cent of the business last year — it's now dropped to 12 per cent.
Ottawa monitoring situation
In a statement to CBC News, the federal government said it "understands that the evolving dynamics in the Canada–U.S. relationship have direct and varying impacts on the tourism sector across the country, including Indigenous tourism operators."
It said it's "monitoring developments in this important sector and remains engaged with all tourism partners, including Indigenous partners."
Ottawa noted that more Americans visited Canada in the first quarter of 2025 compared to the same period last year, adding there has been an increase in bookings to Canada from overseas travellers from countries such as France, the U.K. and Mexico.
The federal government said it has invested $20 million to support more than 330 Indigenous tourism businesses through the Indigenous Tourism Fund, and 15 per cent of the Tourism Growth program is set aside for Indigenous-led tourism programs.
While many Indigenous tourism businesses say they are struggling, a smaller eco-resort in B.C. is making some gains.
Klahoose Wilderness Resort, owned by the Klahoose First Nation on B.C.'s Desolation Sound, about 150 kilometres northwest of Vancouver, said its Canadian market has grown about 40 per cent over the last year.
"I think with everything that's going on in the world, a lot of people are looking at what else can I do that's closer to home," said Chris Tait, tourism manager for Klahoose Wilderness Resort.
The business hasn't seen any particular increase in cancellations, and American guests have increased by about 15 to 20 per cent.
But Henry from the Indigenous Tourism Association of Canada said he's not optimistic that Canadian bookings will help the overall industry make up for the loss of American ones.
"We're telling ourselves that domestic tourism is going to somehow mitigate all these problems. … I think it's going to help somewhat, but our U.S. customer base was spending a lot more per person than the average Canadian," he said.
Henry said the industry is trying to pivot to focus on other international markets.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Canada's Gilgeous-Alexander agrees to massive 4-year extension with NBA champion Thunder: reports
Canada's Gilgeous-Alexander agrees to massive 4-year extension with NBA champion Thunder: reports

CBC

time16 minutes ago

  • CBC

Canada's Gilgeous-Alexander agrees to massive 4-year extension with NBA champion Thunder: reports

Social Sharing Shai Gilgeous-Alexander and the Oklahoma City Thunder have agreed on a record-setting 4-year, $285 million US extension that would give him the highest single-season average salary in NBA history, a person with knowledge of the agreement said Tuesday. The person spoke to The Associated Press on condition of anonymity because the deal has not been publicly announced and likely won't be until the league's moratorium on most offseason signings is lifted on Sunday. ESPN first reported on the agreement. News of the deal comes on Canada Day, a fitting coincidence for the 26-year-old from Hamilton who is coming off a season like few others in NBA history. Not only did Gilgeous-Alexander lead the Thunder to their first NBA championship and the league's best record, he swept most major individual awards — winning regular-season and NBA Finals MVP honors and the scoring title. The supermax extension was not unexpected. It was a question of timing; he could have taken a deal with an even higher total value next summer. Based on the NBA's most recent salary cap projections — the exact numbers will not be finalized until June 2027 — Gilgeous-Alexander would make somewhere around $63 million in the first season and nearly $79 million during the 2030-31 season. That would put him at an average payout of about $1 million per regular season game, and would be the highest single-season salary in NBA history. Gilgeous-Alexander didn't enter the league with superstar expectations. He was the 11th overall pick in the 2018 draft, and he was traded from the Los Angeles Clippers to the Thunder after his rookie year. He has been on an upward trajectory ever since, and Thunder general manager Sam Presti believes that will continue. "He's gotten better every single year," Presti said. "His mindset has allowed him to take these steps and also not — I don't feel like his progress is, like, volatile. I don't know if that makes sense, but I don't feel like it's built on things that can't be repeated and built up again." Presti referred to Gilgeous-Alexander as a "basketball artist" because he has the emotional intelligence to know when to call upon his various gifts. "I just think he's got left and right brain working, and I think when you think about people that are extremely successful in what they do, they can't operate all on one side or the other," Presti said. "People have to have — to me, the great people in life, business, sports, any industry, have to be able to access both sides, a creative side and then also a very objective side." The Thunder are set to be contenders for years. Their best player is in place long-term, all their major players are under contract through at least next season and Presti has a slew of draft picks stashed from previous trades.

REPEAT/Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures
REPEAT/Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures

National Post

time35 minutes ago

  • National Post

REPEAT/Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures

Article content Article content – Funding agreement contemplates a conversion formula with a potential 30% premium upon conversion and positions the Company for growth, and accelerated advancement of its clinical pipeline programs, CYB003 and CYB004 – Article content Article content TORONTO — Cybin Inc. (NYSE American: CYBN) (Cboe Canada: CYBN) (' Cybin ' or the ' Company '), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce the Company has entered into a securities purchase agreement (the ' Securities Purchase Agreement ') with High Trail Special Situations LLC (' High Trail '), pursuant to which the Company agreed to sell and issue to High Trail up to US$500,000,000 in aggregate principal amount of unsecured convertible debentures (the ' Convertible Debentures '). The sale and issue of US$50,000,000 principal amount of Convertible Debentures was completed on June 30, 2025 (the ' Private Placement '). The sale and issue of US$450,000,000 of the principal amount of Convertible Debentures will be determined at a future date, upon mutual agreement of the parties. Article content 'This financing represents a major inflection point for Cybin and supports our position as a leader within our sector,' said Doug Drysdale, Chief Executive Officer of Cybin. 'High Trail Capital is an experienced investor, and its confidence and appreciation of our breakthrough clinical data and intellectual property portfolio recognize the potential of the Company. This financing comes at an opportune time for Cybin, as we advance our lead programs, CYB003 and CYB004, in Phase 3 and Phase 2, respectively. CYB003 demonstrated over 70% remission rates and continued durability over 12 months for patients with uncontrolled depression. We await the conclusion of our CYB004 Phase 2 proof-of-concept study, in patients with generalized anxiety disorder,' said Drysdale. Article content Joseph Gunnar & Co., LLC acted as the sole placement agent in connection with this transaction. Article content Pipeline Acceleration Drives Multiple Value Creation Catalysts Article content The funding will accelerate Cybin's clinical-stage programs across multiple high-value indications: Article content CYB003 Program Achievements: Article content Breakthrough Clinical Results: Unprecedented 71% remission rate in major depressive disorder at 12 months after two 16 mg doses in Phase 2 study Durability advantage: 12-month sustained efficacy demonstrating long-term therapeutic benefit FDA Recognition: Breakthrough Therapy Designation received, expediting regulatory pathway Multinational Phase 3 PARADIGM program underway Article content CYB004 Program Momentum: Article content Dual Indication Strategy: Expanding addressable market opportunity Phase 2 GAD study expected to complete around mid-year 2025 1 Article content Commercialization Infrastructure: Article content Value Catalysts Drive Sustained Momentum Article content Near-Term Catalysts: Article content CYB004 Phase 2 GAD study expected to complete around mid-2025 1 Initiation of second CYB003 pivotal study, EMBRACE, around mid-2025 1 EXTEND study initiation imminent 1 Article content Medium-Term Catalysts (2025-2026): Article content Transaction Terms Article content The Convertible Debentures have a two-year term from the closing date (the ' Term '). The Company shall pay guaranteed interest equal to 5.5% of the principal per annum for the Term. Such interest was pre-paid on closing. Upon the occurrence of an event of default, interest shall increase to a rate of 18% per annum on the outstanding principal balance. Pursuant to the terms of the Securities Purchase Agreement, the Company and High Trail may, upon mutual consent, enter into subsequent securities purchase agreements for the purchase and sale of up to an additional US$450,000,000 principal amount of Convertible Debentures, in tranches, in amounts on such dates as may be mutually agreed and each subsequent tranche shall include prepaid interest at a rate of 9.5%. Article content Subject to the terms of the Securities Purchase Agreement and the Convertible Debentures, High Trail will be entitled to convert the principal amount of, and accrued and unpaid interest, if any, on each Convertible Debenture, in whole or in part, from time to time, into common shares in the capital of the Company (the ' Common Shares ') at a conversion price per Common Share equal to the lower of (a) 130% of the volume weighted average price (' VWAP ') of the Common Shares on the day prior to the initial issuance of the Convertible Debentures, or (b) the VWAP of the Common Shares during the five trading days immediately prior to the date of conversion. Article content The Company, in its sole discretion, may prepay any outstanding amount under the Convertible Debentures, in whole or in part, in cash by providing High Trail with advance written notice prior to such prepayment. The prepayment shall include, (i) if paid during the first year after closing, a 5% prepayment premium on the amount of the prepayment or (ii) if paid thereafter, a 3% prepayment premium on the amount of the prepayment. Article content The terms of the Convertible Debentures restrict the conversion of Convertible Debentures by High Trail if such a conversion or exercise would cause High Trail, together with any affiliate thereof, to beneficially own in excess of 4.99% of the number of Common Shares outstanding immediately after giving effect to such conversion. Article content The Company intends to use the net proceeds from the Private Placement for working capital and general corporate purposes. Article content The Convertible Debentures were offered on a private placement basis pursuant to prospectus exemptions in Canada and pursuant to exemptions and exclusions from the registration requirements of the United States Securities Act of 1933, as amended, and applicable state securities laws. The Company has agreed to use commercially reasonable efforts to: (a) file a prospectus supplement to the Company's base shelf prospectus dated August 17, 2023, as amended on December 22, 2023, April 8, 2024 and January 6, 2025, with applicable Canadian securities regulators to qualify the secondary market sales of the Common Shares in the United States; and (b) either (i) prepare and file the Canadian prospectus supplement with the United States Securities and Exchange Commission, or (ii) file a prospectus supplement pursuant to General Instruction II.L of Form F-10 with the United States Securities and Exchange Commission to the Company's registration statement on Form F-10 (File No. 333-284173), which was declared effective by the SEC on January 14, 2025, or on such other form as may be available to the Company, in either case qualifying the resale of the Common Shares underlying the Convertible Debentures. Article content No securities regulatory authority has either approved or disapproved of the contents of this news release. This news release is not an offer to sell or the solicitation of an offer to buy the securities in the United States or in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to qualification or registration under the securities laws of such jurisdiction. The securities being offered have not been registered under the U.S. Securities Act, and such securities may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from U.S. registration requirements and applicable U.S. state securities laws Article content About Cybin Article content Cybin is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions. Article content With promising proof-of-concept data, Cybin is working to change the mental health treatment landscape through the introduction of intermittent treatments that provide long lasting results. The Company is currently developing CYB003, a proprietary deuterated psilocin analog, in Phase 3 studies for the adjunctive treatment of major depressive disorder and CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in a Phase 2 study for generalized anxiety disorder. The Company also has a research pipeline of investigational, 5-HT-receptor focused compounds. Article content Founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For Company updates and to learn more about Cybin, visit or follow the team on X, LinkedIn, YouTube and Instagram. Article content There is no assurance that timelines will be met. Anticipated timelines regarding the initiation, advancement and results of clinical trials are based on reasonable assumptions informed by current knowledge and information available to the Company. See 'Cautionary Notes and Forward-Looking Statements'. Article content Cautionary Notes and Forward-Looking Statements Article content Certain statements in this news release constitute forward-looking information and forward-looking statements within the meaning of applicable securities laws (together, 'forward-looking statements'). Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as 'may', 'should', 'could', 'intend', 'estimate', 'plan', 'anticipate', 'expect', 'believe' or 'continue', or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the use of Private Placement proceeds; the conversion of the Convertible Debentures into Common Shares; the sale and issue of US$450,000,000 principal amount of Convertible Debentures at a future date; CYB004 Phase 2 GAD study expected to complete around mid-2025; Initiation of second CYB003 pivotal study, EMBRACE, around mid-2025; the Company's Medium-Term Catalysts for 2025-2026; Phase 3 PARADIGM program enrollment acceleration; the Company's ability to achieve commercial success; and the Company's ability to address the need for new and innovative treatment options for people who suffer from mental health conditions. Article content These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the psychedelics market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; implications of disease outbreaks on the Company's operations; and the risk factors set out in each of the Company's management's discussion and analysis for the three and nine month periods ended December 31, 2024 and the Company's annual information form for the year ended March 31, 2024, which are available under the Company's profile on and with the SEC on EDGAR at Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law. Article content Cybin makes no medical, treatment or health benefit claims about Cybin's proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybin's performance and operations. Article content Article content Article content Article content Article content Contacts Article content Investor & Media Contact Article content : Article content

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store